Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 101 results for "novartis india"

Novartis India Q2 profit declines 69%


Novartis India Limited (NIL) has been ranked 413th in the Business Today magazine's Most Valuable Top-500 Companies, based on average market capitalisation for Apr- Sep 2014 . The average market capitalisation of NIL was at Rs1,877 crore ( Rs1,536 ... 4 Traders, 5 days ago
Novartis India : Q2 PROFIT NOSEDIVES 69% 4 Traders, 2 weeks ago

8 images for novartis india, 2 weeks ago
Pharma Letter, 2 weeks ago
Yahoo! News, 3 weeks ago
Reuters UK, 3 weeks ago
Reuters, 3 weeks ago
Pharmaceutical Technology, 1 month ago
Pharma Letter, 1 month ago
West Australian, 1 month ago

dna impact: Tata Memorial to repay cancer patients

Tata Memorial Hospital has decided to reimburse cancer patients who were overcharged for a Novartis-branded oncology medicine over the last nine months. The hospital admitted to overcharging at its two pharmacies (one each in the main building and the Homi ...
 DNA4 days ago NOVARTIS : Tata Memorial to repay cancer patients  4 Traders1 day ago

Why the Tata Memorial incident should be a wake-up call for other hospitals, pharma companies and regulators

'A stitch in time saves nine' is a befitting phrase in the case of India's most reputed cancer speciality healthcare service provider, the Tata Memorial Hospital (TMH) at Parel in Mumbai. Despite having knowledge about downward price revision they ...
 DNA India2 days ago
Financial Express

Another shot at delisting likely after Sebi norms

With the Securities and Exchange Board of India (Sebi) expected to announce easier or simpler rules for share delisting on Wednesday, many companies will attempt taking that route, said merchant bankers privy to information. Essar Shipping is one ...
 Financial Express1 week ago

Net sales of 50 major pharma cos up by 14%, EBDITA by 15.5% in first half of 2014-15

Despite reduction in prices of several medicines by NPPA, quality problems with US FDA, competition and slowdown in approvals, 50 top Indian pharmaceutical companies registered satisfactory growth in net sales and earnings before depreciation, ...
 PharmaBiz3 days ago

Why Are Drug Costs So High in the United States?

The United States has the dubious honor of paying the highest costs for drugs in the world, even compared with other wealthy nations, such as Canada, Germany, and Japan. The difference in price can often be substantial, especially among the newer ...
 Medscape6 days ago

Outcome of board meeting of Novartis India

Held on 07 November 2014
 Business Standard2 weeks ago Novartis India: Outcome of board meeting  Money Control2 weeks ago Novartis India to hold board meeting  Capital Market4 weeks ago
Business Standard

Cipla drug kicks off patents row

Taking the patent battle to Novartis, India’s Cipla has launched low-cost generic version of the Swiss drug maker’s respiratory drug Indacaterol sold under the Onbrez brand, while asking the government to revoke patents over the medicine. Cipla, which has ...
 Asian Age3 weeks ago Cipla asks government to revoke five patents held by Novartis  Economic Times4 weeks ago Cipla asks govt to revoke Novartis patent; launches its drug  The Hindu3 weeks ago Cipla asks government to revoke Novartis' patent; launches its drug  Economic Times3 weeks ago

Pharma companies in consonance with implementing revised drug prices: Delhi High Court told

NEW DELHI: The Centre today told the Delhi High Court that pharmaceutical companies, including Novartis India Limited and Cipla Ltd, appear to be in "consonance" with implementation of the revised drug pricing and the two sides are "very close" to ...
 Economic Times3 weeks ago HC asks pharma companies, Centre to resolve the drug pricing  Business Standard2 months ago Delhi High Court Asks Pharma Companies, Centre to Resolve the Drug Pricing  NDTV2 months ago Pharma firms in consonance with implementing revised drug  Press Trust of India3 weeks ago


The National Pharmaceutical Pricing Authority (NPPA) has imposed a penalty of Rs300 crore on Novartis India Ltd. The penalty is for overcharging consumers on sale of Voveran, pain killer drug. Novartis India has received a show cause ...
 4 Traders1 month ago Novartis down; NPPA imposes fine  India Infoline1 month ago Novartis India Ltd clarifies on penalty levied by NPPA  Equity Bulls1 month ago Novartis clarifies on NPPA penalty news; stock closes flat  India Infoline1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less